Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q2

9776.TEDINET S100S73T
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥9.9bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥20.1bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥10.0bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥291m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥493m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥296m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥589m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥386m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥508m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥226m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥569m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥258m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥226m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥319m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥16.7bnat 2023-09-30Cons.Assets
Total assets¥16.5bnat 2023-03-31Cons.Assets
Total assets¥16.2bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥5.7bnat 2023-09-30Cons.Liabilities
Total liabilities¥5.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥11.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥10.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥10.5bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥4.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.7bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥4.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥810m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥674m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥171m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥409m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥292m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥238m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥348m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥223m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥67.942023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥66.232023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥170.532022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥77.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥54.092022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio64.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio64.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥56m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥41m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥78m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥377m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥798m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥492m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥306m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7m
—segment totalrevenue2023-04-01 → 2023-09-30¥10.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥9.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥306m
—segment totalsegment profit2023-04-01 → 2023-09-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥10.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥308m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥489m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥46m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥30m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥371m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥356m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥805m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥472m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥333m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥6m
—segment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥333m
—segment totalsegment profit2022-04-01 → 2022-09-30¥721m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥10.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥334m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥751m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 549
ItemContextValueUnit
Retained earningsPrior1YearInstant9304184000JPY
Retained earningsCurrentQuarterInstant9453876000JPY
Treasury stockPrior1YearInstant-757451000JPY
Treasury stockCurrentQuarterInstant-757451000JPY
Shareholders equityPrior1YearInstant10545353000JPY
Shareholders equityCurrentQuarterInstant10695045000JPY
Valuation difference on available for sale securitiesPrior1YearInstant40044000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant65728000JPY
Valuation and translation adjustmentsPrior1YearInstant40044000JPY
Valuation and translation adjustmentsCurrentQuarterInstant65728000JPY
Non controlling interestsPrior1YearInstant295588000JPY
Non controlling interestsCurrentQuarterInstant263378000JPY
Net assetsPrior1YearInstant10880986000JPY
Net assetsCurrentQuarterInstant11024152000JPY
Liabilities and net assetsPrior1YearInstant16521281000JPY
Liabilities and net assetsCurrentQuarterInstant16712144000JPY
Net salesPrior1YTDDuration9964353000JPY
Net salesCurrentYTDDuration9862397000JPY
Cost of salesPrior1YTDDuration6817070000JPY
Cost of salesCurrentYTDDuration6906947000JPY
Gross profitPrior1YTDDuration3147282000JPY
Gross profitCurrentYTDDuration2955450000JPY
Selling general and administrative expensesPrior1YTDDuration2654541000JPY
Selling general and administrative expensesCurrentYTDDuration2664149000JPY
Operating incomePrior1YTDDuration492741000JPY
Operating incomeCurrentYTDDuration291301000JPY
Interest income noiPrior1YTDDuration108000JPY
Interest income noiCurrentYTDDuration86000JPY
Dividends income noiPrior1YTDDuration2818000JPY
Dividends income noiCurrentYTDDuration2804000JPY
Rent income noiPrior1YTDDuration21003000JPY
Rent income noiCurrentYTDDuration20027000JPY
Subsidy income noi bountyPrior1YTDDuration90906000JPY
Subsidy income noi bountyCurrentYTDDuration13704000JPY
Other noiPrior1YTDDuration14928000JPY
Other noiCurrentYTDDuration5079000JPY
Non operating incomePrior1YTDDuration129765000JPY
Non operating incomeCurrentYTDDuration41702000JPY
Interest expenses noePrior1YTDDuration4124000JPY
Interest expenses noeCurrentYTDDuration3700000JPY
Cost of lease revenue noePrior1YTDDuration22002000JPY
Cost of lease revenue noeCurrentYTDDuration20000000JPY
Subsidy refund amountPrior1YTDDuration－JPY
Subsidy refund amountCurrentYTDDuration8394000JPY
Other noePrior1YTDDuration6923000JPY
Other noeCurrentYTDDuration4559000JPY
Non operating expensesPrior1YTDDuration33050000JPY
Non operating expensesCurrentYTDDuration36654000JPY
Ordinary incomePrior1YTDDuration589456000JPY
Ordinary incomeCurrentYTDDuration296350000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass